Sickle Archives - Precision Medicine Group

Webinar: Cell and Gene Therapies – How High Can Prices Go?

Brandon Atienza2023-04-20T10:26:48-04:00Cell & Gene Therapy, Events, Thought Leadership|

Join our experts on April 26, 2023 at 9AM EST as we dive into a powerful 30 minute webinar followed by live Q&A.

This ON24 webinar will discuss how cell and gene therapies can be justifiably priced at different levels. We will explore just how high they can extend and also how we can collectively ensure that patients can access these innovations when they are needed. This discussion will be led by David Carr: Senior Director, Global Pricing and Market Access (PRECISIONadvisors), Richard Macaulay: SVP, Global Pricing and Market Access (PRECISIONadvisors).

(more…)

Announcing Cell & Gene Day – May 11, 2023

Connor Rudny2023-04-19T14:19:44-04:00Cell & Gene Therapy, News, Thought Leadership|

Even as cell and gene therapies inspire hope for patients who previously had none, the path to commercialization is littered with roadblocks. There is a pressing need for increased efficiency, enhanced safety, and innovative approach to pricing and access. How are leading CGTx innovators approaching these challenges? Find out at Cell & Gene Day 2023, a free virtual event.

(more…)

Precision for Medicine Expands Advanced Tissue Profiling and Genomic Capabilities with new Houston Laboratory

Carlos Bonilla2023-04-10T17:17:59-04:00News, Press Releases|

Houston is one of seven global Precision specialty labs addressing the rising demand for rapid, comprehensive biomarker data to support the development of advanced therapies and diagnostics

HOUSTON, TX, April 12, 2023 – Precision for Medicine, the first global biomarker-driven clinical research organization, today announced the expansion of its cell biology and genomics laboratory in Houston, TX, proliferating the company’s global biomarker capabilities and laboratory operations.

(more…)

White Paper: “Preventative” Gene Therapies: Perspectives on Payer Access Challenges and Solutions

Brandon Atienza2023-04-06T15:48:16-04:00Cell & Gene Therapy, News, Thought Leadership|

Gene therapies offer hope for patients with severe genetic diseases by providing long-term benefits and even cures. However, the challenges of evaluating the long-term benefits of these therapies from a payer perspective are considerable. This white paper by PRECISIONadvisors highlights the shift of gene therapy research into more prevalent diseases, and outlines how manufacturers and payers can co—create evidence requirements and models to optimize launch success and sustainability.

(more…)

Conference: Gene Therapy for Rare Disorders, 2023

Brandon Atienza2023-03-21T11:25:55-04:00Cell & Gene Therapy, Events, Thought Leadership|

Precision will be at this year’s Gene Therapy for Rare Disorders on March 20-23, 2023, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for gene therapies.

Speaking Engagements
Detailed descriptions for each speaking engagement are included below.

Precision ADVANCE will have a plenary speaking position on March 21, 2023, 8:30 – 9:00 am.
Project Farma will be facilitating a plenary panel discussion ” Current Trends in Technical Operations for Rare Disorders” on March 21, 2023, 10:45 – 11:15 am.
Project Farma’s Tony Khoury (EVP, Project Farma) will be joining the Manufacturing track panel discussion, “Capacity versus Capability – Moving Towards Innovative Manufacturing Processes,” on March 21, 2023, 11:15 – 11:45 am.
Precision ADVANCE will hold a drinks reception on March 21, 2023, at 6:10 pm in the Grand & Liberty Ballroom.

Connect with our Advanced Therapy experts

Visit us at booth 13 in the exhibition area
Schedule in-person or virtual meetings by clicking here: https://bit.ly/precisionmedicinegrp
Attend our ADVANCE-sponsored Drinks Reception on March 21, 2023, at 6:10 PM ET

(more…)

On-Demand: Let’s Talk: Moving CGTx Clinical Development Forward in 2023

Brandon Atienza2023-03-09T12:12:56-05:00Cell & Gene Therapy, Events|

Sponsored by Precision ADVANCE, this Endpoints webinar will convene leading advanced therapy experts to discuss the future of CGTx clinical development. This discussion will be moderated by Teresa Pokladowski: Regional VP, Clinical Business Solutions (Precision for Medicine), and include insights from Kinnari Patel: President & COO (Rocket Pharmaceuticals), Suma Krishnan: Founder & President (Kystal Biotech), Dawn Buchanan: VP Clinical Operations (AffyImmune), and Ramona Repaczki-Jones: Executive Director, Commercial Treatment Center Operations, Cell Therapy (lovance Biotherapeutics, Inc).

(more…)

White Paper: What’s Next for Cell and Gene Therapies in 2023 and Beyond

Brandon Atienza2023-02-10T15:51:26-05:00Cell & Gene Therapy, Thought Leadership|

The cell and gene therapy (CGTx) sector has flourished in recent years due to continued investor confidence. However, the present downturn in public markets has negatively affected that confidence, raising questions about the sector’s prospects for 2023 and beyond.

This white paper is based on a panel discussion at the Cell & Gene Meeting on the Mesa (October 11, 2022), sponsored by Precision ADVANCE, focusing on the future of advanced therapies. The panel included insights from the following industry leaders:

Anshul Mangal: President (Project Farma & Precision ADVANCE)
Stewart Abbot: Chief Scientific Officer (Turnstone Biologics)
Laura Lande-Diner: Chief Business Officer (Satellite Bio)
Robert Peters: Chief Scientific Officer (Ensoma)
Deborah Phippard: Chief Scientific Officer (Precision For Medicine)

(more…)

White Paper: State of the Union for Advanced Medicines

Brandon Atienza2023-02-13T11:09:46-05:00Cell & Gene Therapy, Thought Leadership|

The cell and gene therapy (CGTx) sector has flourished over the last 2 to 5 years due to continued investor confidence. However, the recent downturn in public markets has undermined that confidence.

This white paper is based on a panel discussion, sponsored by Precision ADVANCE, featuring insights from diverse industry perspectives on the current state of the CGTx sector; the investment landscape; scientific and technical advances; progress in drug development, manufacturing, regulatory, pricing, and reimbursement; and expected key trends in 2023 and beyond. Hosted by Endpoints News, the panel included insights from the following industry leaders:

Anshul Mangal: President (Project Farma & Precision ADVANCE)
Dave Greenwald: Vice President of Business Development (Deerfield Management)
Rajul Jain: Managing Director (Vida Ventures)
Joseph LaBarge: Chief Executive Officer (Apertura Gene Therapy)
Adrian Woolfson: Executive Chairman, President and Co-Founder (Replay Bio)
Phil Cyr: Executive Vice President (Precision Value & Health)

(more…)

On-Demand: The Hitchhiker’s Guide to CGTx in 2023

Brandon Atienza2023-01-30T14:52:17-05:00Cell & Gene Therapy, Events|

Cell & gene therapy advancement has increased at an immense rate over the past decade. With the right tools and guidance, patients can receive new forms of treatments. Staying up to date with progress in the field is as important as ever with the constant strive to improve technology, especially in areas like regulatory pathways, novel technologies, and CMC and manufacturing trends.

Sponsored by Precision ADVANCE, this Life Science Connect webinar will convene leading advanced therapy experts to discuss innovation and expectations for advanced therapies in 2023. This discussion will be moderated by Andy Kinley (VP of Innovation & Clinical Science, Precision for Medicine), and include insights from Peter Andersen (CSO, Vita Therapeutics), Deb Phippard (CSO, Precision for Medicine), Palani Palaniappan (CTO, Flagship Pioneering), Phil Cyr (SVP, Precision Value & Health), and Charlie Harper (VP, Project Farma).

(more…)

Leaping the Next Hurdle in CAR T-Cell Therapies

Lisa Lewin2022-12-14T10:10:54-05:00Cell & Gene Therapy, Thought Leadership|

While chimeric antigen receptor (CAR) T-cell therapy has demonstrated its ability to produce responses in refractory tumors, many challenges remain with the therapies. Precision’s Phil Cyr discusses some of these challenges as well as questions and research that remain to be answered.

Read the full article here!